QPPV.COM KNOWLEDGE ASSESSMENT

FDA Adverse Event Monitoring System (AEMS): Dashboard Use and Pharmacovigilance Practice

Test your understanding of the concepts covered by FDA Adverse Event Monitoring System (AEMS): Dashboard Use and Pharmacovigilance Practice.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A submitter uses FDA's Safety Reporting Portal rather than ESG NextGen for the relevant post-marketing reporting pathway. What does the article say about the ESG NextGen E2B(R3) change?

The submitter must switch to ESG NextGen by 1 October 2026. The submitter must use E2B(R2) indefinitely. The submitter does not need to take action for this particular ESG NextGen change. The submitter is exempt from all FDA safety-reporting requirements.

Question 2 of 10 A product's AEMS report count rises over several weeks. Which conclusion is best supported by that observation alone?

The product's underlying event incidence has increased. More reports were displayed under the relevant query, warranting assessment of data and context but not establishing an increase in risk. The product is less safe than medicines with fewer reports. FDA has confirmed a new causal association.

Question 3 of 10 A company submits an in-scope post-marketing ICSR for a human drug through ESG NextGen after 1 October 2026. Which standard applies under the article's described schedule?

E2B(R2), unless FDA has first confirmed that the case is serious. E2B(R3) only if the report originated outside the United States. No electronic standard applies because AEMS is only a public dashboard. E2B(R3), for the specified post-marketing ICSR scope submitted through ESG NextGen.

Question 4 of 10 What should QPPV oversight of an organisation's use of AEMS primarily focus on?

Treating every fluctuation in the dashboard as a formal signal requiring immediate regulatory action. Ensuring relevant findings are identified, appropriately escalated and documented, with decisions supported by review and evidence. Replacing internal case processing with dashboard counts. Confirming that every FDA-listed potential signal is a proven product risk.

Question 5 of 10 Why might a dashboard result differ from an analysis of FDA's quarterly data files?

One source must be incorrect because both always use identical data and filters. The dashboard is limited to confirmed causal cases, while the files contain all reports. The dashboard and files can differ in data cut, fields and processing; the extract and analysis choices should be recorded. Quarterly files exclude all follow-up information.

Question 6 of 10 A sponsor generalises the 1 October 2026 E2B(R3) date to mean every safety submission to FDA must use ESG NextGen. What is the best correction?

The date applies only to commercial IND reports, not post-marketing ICSRs. Every safety submission must use ESG NextGen, but E2B(R3) is optional. The date applies only to dashboard searches, not electronic reporting. The article describes a scoped requirement for specified post-marketing ICSRs submitted through ESG NextGen, not every FDA safety-report pathway.

Question 7 of 10 A safety analyst wants to compare report counts for two products and use the result to rank their safety. Why is this method unsound?

Counts can be affected by exposure, time on market, indication, reporting behaviour and data quality, and do not alone establish comparative risk. AEMS does not allow searches for more than one product. Product comparisons are valid only when both products have the same number of reactions. A product with fewer reports must have a lower incidence regardless of exposure.

Question 8 of 10 A product does not appear on FDA's quarterly potential-signal page. Which conclusion is justified?

FDA has not reviewed the product's safety. No safety concern exists for the product. The product has passed a formal FDA causality assessment. The product is not listed in that defined public reporting mechanism; this does not establish that FDA has never reviewed it or that no concern exists.

Question 9 of 10 A team wants to use a dashboard query to investigate a newly described adverse event. Which approach best supports a useful and reproducible analysis?

Search the brand name, record the largest displayed number, and compare it with another product's number. Search all available terms without filters so the dashboard captures every possible report. Wait until the dashboard count stops changing before documenting the query. Define the safety question, select relevant product and reaction terms and filters, and preserve the query date and output.

Question 10 of 10 An analyst finds an older FDA page labelled “FAERS Public Dashboard.” What is the most appropriate conclusion?

Legacy names and paths may remain in use even though the underlying FAERS data were moved to the AEMS environment. The page must contain data that were excluded from AEMS. The name proves that the page is no longer an FDA source. The page can be used only for reports submitted before AEMS launched.

QPPV.com

FDA Adverse Event Monitoring System (AEMS): Dashboard Use and Pharmacovigilance Practice

Cookie Settings